37
Participants
Start Date
September 16, 2015
Primary Completion Date
July 2, 2018
Study Completion Date
July 2, 2018
Glembatumumab Vedotin
Given IV
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Roswell Park Cancer Institute, Buffalo
University of Pennsylvania/Abramson Cancer Center, Philadelphia
Ohio State University Comprehensive Cancer Center, Columbus
Mayo Clinic, Rochester
UC Comprehensive Cancer Center at Silver Cross, New Lenox
University of Chicago Medicine-Orland Park, Orland Park
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine, St Louis
University of Kansas Cancer Center, Kansas City
University of Kansas Clinical Research Center, Fairway
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
M D Anderson Cancer Center, Houston
University of Colorado Hospital, Aurora
Huntsman Cancer Institute/University of Utah, Salt Lake City
Mayo Clinic Hospital, Phoenix
Mayo Clinic in Arizona, Scottsdale
Mayo Clinic in Florida, Jacksonville
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Penn State Milton S Hershey Medical Center, Hershey
National Cancer Institute (NCI)
NIH